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Abstract
Background: Our aims were to evaluate critically the evidence from systematic reviews as well as narrative reviews
of the effects of melatonin (MLT) on health and to identify the potential mechanisms of action involved.
Methods: An umbrella review of the evidence across systematic reviews and narrative reviews of endogenous and
exogenous (supplementation) MLT was undertaken. The Oxman checklist for assessing the methodological quality
of the included systematic reviews was utilised. The following databases were searched: MEDLINE, EMBASE, Web of
Science, CENTRAL, PsycINFO and CINAHL. In addition, reference lists were screened. We included reviews of the
effects of MLT on any type of health-related outcome measure.
Results: Altogether, 195 reviews met the inclusion criteria. Most were of low methodological quality (mean -4.5,
standard deviation 6.7). Of those, 164 did not pool the data and were synthesised narratively (qualitatively) whereas
the remaining 31 used meta-analytic techniques and were synthesised quantitatively. Seven meta-analyses were
significant with P values less than 0.001 under the random-effects model. These pertained to sleep latency,
pre-operative anxiety, prevention of agitation and risk of breast cancer.
Conclusions: There is an abundance of reviews evaluating the effects of exogenous and endogenous MLT on
health. In general, MLT has been shown to be associated with a wide variety of health outcomes in clinically and
methodologically heterogeneous populations. Many reviews stressed the need for more high-quality randomised
clinical trials to reduce the existing uncertainties.
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Background
Circadian rhythms are biological processes that display
endogenous, entrainable oscillation cycles that last ap-
proximately 24 hours (owing to the Earth’s rotation
around its own axis) [1]. These rhythms tune internal
physiology, behaviour and metabolism to external condi-
tions and are considered to be a feature of most living
cells and organisms [1].
At the epicentre of circadian rhythms is melatonin
(MLT) or N-acetyl-5-methoxy tryptamine, an indoleamine
primarily produced by the pineal gland and secreted into
the blood [2, 3]. The indoleamine can be administered ex-
ogenously, i.e. orally, as capsules, tablets or liquids, sublin-
gually, or as transdermal patches. It is available without
prescription (over-the-counter) in many countries for the
treatment of insomnia and depression. MLT synchronises
the internal hormonal environment to the light–dark cycle
of the external environment and controls circadian
rhythms [4, 5]. Unfortunately, at night, artificial lighting
such as light-emitting diodes (LED) continues to activate
the suprachiasmatic nucleus of the brain, suppressing the
natural release of MLT and potentially causing health
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problems [6]. Previous studies have provided evidence
of the role of MLT on the regulation of circadian
rhythms as well as its connection with the development
of various cancers (breast, prostate, endometrial, ovary,
colorectal and skin), cardiovascular diseases, gastro-
intestinal and digestive problems, diabetes, obesity,
depression, sleep deprivation, premature ageing and
cognitive impairment [7–16].
A comprehensive, informed and up-to-date review of
the current knowledge on the effects of MLT on health
is not only timely but urgent, given the technological
and lifestyle changes, e.g. chronodisruption, following
the overwhelming use of the LEDs omnipresent in com-
puters, smartphones and tablets.
Therefore, the objectives of this umbrella review were
to evaluate the evidence for the effects of MLT on health
from the published literature, specifically systematic re-
views (SRs) and narrative reviews (NRs), to investigate
the potential mechanisms of action and to identify which
health outcomes are associated with the production and/
or supplementation of MLT.
Methods
The Cochrane Handbook for Systematic Reviews of inter-
ventions and the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines [17]
were adhered to while writing and reporting this review
(Prospero registration number: CRD42016039840; avail-
able at www.crd.york.ac.uk/PROSPERO) [18].
Literature search and eligibility criteria
For the electronic search, the following databases were
searched for entries from January 1996 until July 2017:
MEDLINE (via Ovid), EMBASE (via Ovid), Web of
Science, CENTRAL (Wiley), PsycINFO (Ovid) and
CINAHL (via EBSCO). We hypothesised that any signifi-
cant reviews or studies would have been captured by re-
views conducted since January 1996 (our search start
date). A detailed search strategy for MEDLINE is pre-
sented in the Appendix. In addition to the electronic
searches, the reference lists of all eligible articles were
reviewed for further potentially relevant studies. Only data
from the published papers were used; the study authors
were not contacted.
We included SRs (defined as research articles with a
replicable methods section, e.g. searches, eligibility
criteria and critical appraisal of primary studies) [19] or
NRs (defined as articles without a replicable methods
section) [20] of studies involving both healthy and ill in-
dividuals of any age and gender using both endogenous
and exogenous MLT and MLT agonists. Reviews that re-
lied on data from animal, human or/and in vitro studies
with any type of health-related outcome measures were
eligible. All SRs and NRs that are for the same
associations throughout the search period regardless of
the amount and level of overlap, i.e. one primary study
included in two or more reviews and/or two or more
identified reviews on the same topic, were eligible. We
excluded reviews of plants, abstracts or review protocols
and reviews not published in English.
Study selection
The data screening and selection process were performed
by the first reviewer (PP) and verified and validated by a
second reviewer (BMK). All identified references were
imported into EndNote (X7.7.1). The search results from
all the bibliographic searches were merged and duplicate
records removed.
Data extraction
Working in groups of two, four authors (BMK, UD, GD
and SB) independently extracted relevant information from
the studies included using a custom-made data extraction
form. The data were subsequently validated by a fifth au-
thor (PP). The following information was extracted from
the reviews included: first authors’ names and publication
date, total number of primary studies, total number of pa-
tients included, quality of SRs (Oxman checklist score),
quality of primary studies (low, moderate or high as
determined by the authors of the reviews), subject/
condition/indication, administration of MLT (dose,
route, frequency and duration), details of any meta-
analyses (MAs), health outcomes/effects/overall results,
confounders, and any additional comments. Any disagree-
ments were resolved by discussion between the authors.
Quality assessment
The methodological quality of SRs was independently eval-
uated by five reviewers using the Oxman checklist [21].
This validated tool assesses the quality of review articles
across nine domains: (1) reporting of search strategy, (2)
comprehensiveness of searches, (3) repeatable eligibility cri-
teria, (4) avoidance of selection bias, (5) presence of a valid-
ity assessment tool, (6) use of the validity assessment tool,
(7) robustness of data analysis, (8) appropriateness of data
analysis and (9) supportiveness of conclusions. Each ques-
tion was scored as 1 (fulfilled), 0 (partially fulfilled) or -1
(not fulfilled). A score of 1 or below indicates extensive
flaws, 2–3 indicates the presence of major flaws, 4–5 means
minor flaws and 6–9 indicates minimal or no flaws. Again,
any disagreements (N = 6) were resolved by discussion be-
tween the authors.
Statistical analysis
The results from NRs or SRs that did not pool data
quantitatively (N = 164) are presented narratively using
descriptive tables. Sub-group analyses were conducted
for the subset of 31 SRs that had pooled their data
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quantitatively. For that purpose, the approach by Bellou
et al. [22] was used. For each health outcome, we calcu-
lated the number of participants and original studies
involved in the MA, summary effect sizes [with 95%
confidence intervals (CI) and P values] using both ran-
dom- and fixed-effects models. The 95% prediction
interval (PI) was calculated, which further accounts for
between-study heterogeneity and estimates the uncer-
tainty around the effect that would be anticipated in a
new study evaluating that same association. Between-
study heterogeneity was measured with the I2 statistic.
An I2 value of 50% or more is considered to represent a
substantial level of heterogeneity, whereas values exceed-
ing 75% are considered to represent considerable hetero-
geneity. These values also need to be interpreted in light
of the size and direction of effects and the strength of
the evidence for heterogeneity, based on the P value
from Cochran’s Q test [18]. The evidence of small-study
effects (i.e. the tendency of smaller studies to produce
substantially larger effect size estimates compared to
larger studies) was evaluated by Egger’s regression asym-
metry test [23]. In a more conservative way, a P value
less than 0.10 from Egger’s test was considered to be evi-
dence of small-study effects. Wherever possible, we ex-
tracted the estimate of the largest study (with least
standard error) of each MA from a random-effect model
to interpret the direction and magnitude of the effect
size. We characterised the convincing associations if
they met the following criteria: had significance accord-
ing to a random-effects meta-analysis of less than 0.001,
were based on greater than 1000 participants, had
between-study heterogeneity (I2) < 50% and a 95% PI
excluded the null value, and had no evidence of small-
study effects and excess significance bias. MAs where
the required information was not available were ex-
cluded from mainstream analyses and presented in a
separate table. The statistical analyses were done with
open-source R software (version 3.3.1) for Windows
using the Meta package. The Pieper et al. formula [24]
was used for calculating the amount of overlap (as a per-
centage) of primary trials in the included SRs (i.e., cor-
rected covered area). A corrected covered area within
the range 0–5% indicates a slight overlap, 6–10% indi-
cates a moderate overlap, 11–15% indicates a high over-
lap and > 15% indicates a very high amount of overlap.
Results
Our searches identified a total of 4329 records; 195 re-
view articles met the inclusion criteria (Fig. 1). Table 1
presents the biological mechanisms of action involved.
Tables 2 and 3 summarise MAs of MLT for health with
and without sufficient data for quantitative synthesis,
Fig. 1 Flow diagram for studies included. MLT melatonin
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Table 1 Biological functions and processes that may be affected by MLT and suggested mechanisms of action in various models
Function or process Effects Suggested mechanisms Type of evidence (references)
Cancer Tumour regression; activation of tumour-
suppressive signalling network; oncostatic
activity; modulation of oestrogen and
androgen; immunomodulation or
neuroimmunomodulation; cytoskeletal
modulation; modulation of water transport;
resynchronisation of the intracellular clock
network; modulation of cellular redox status;
haematopoiesis; reduced cardiotoxicity;
enhanced mitochondrial function;
anti-oestrogen; epigenetic regulation;
radioprotection
Reduction of cellular proliferation; free
radical scavenging; inhibition of the uptake
of linoleic acid; stimulation of glutathione
production (γ-glutamylcysteine synthase
and reduced reactants such as hydroxyl
radical, hydrogen peroxide, hypochlorous
acid, singlet oxygen, the peroxynitrite anion
and peroxynitrous acid); blocking cell-cycle
progression from the G phase to the S
phase and by increasing p53, p21 and
p27Kip1 gene and protein expression
(via increased expression of E-cadherin and
β1-integrin proteins); stimulation of
lymphocytes, monocytes, granulocytes,
macrophages, T-helpers (Th1 and Th2), T
and B lymphocytes and thrombocytes;
NK cell activity; platelet generation;
enhancement of the production of
cytokines IL-1, IL-2, IL-4, IL-6, IL-10, IL-12,
IL-24, IFN-γ and TNF-α; co-activation of
protein kinase C and protein kinase A, and
phospholipase C; inhibition of angiogenesis
(via inhibition of endothelin-converting
enzyme-1 and insulin-like growth factor 1);
cell apoptosis; inhibition of 17β-oestradiol;
stimulation of biopterins; microfilament
modulation; switching microfilament
phenotypes; improving oxidative
phosphorylation and increasing ATP
generation; reduced electron leakage and
mPTP opening; decrease in gonadal
steroids; downregulation of the expression
of oestrogen α receptors; potentiation of
cytostatic anti-oestrogen sensitivity of
chemotherapeutic agents; inhibition of
DNA methyltransferase; inhibition of
telomerase; inhibition of metastasis;
mutations in the melatonin receptors
(MLT1 and MLT2); alterations of
arylalkylamine N-acetyltransferase; reduced
thrombocytopenia; inhibition of
prostaglandin E2; inactivation of calmodulin
In vitro, animal and clinical studies, RCTs,
epidemiological studies, SRs
[31, 37, 44, 63, 68, 69, 72–108]
Metabolic and cardiovascular
disorders
Anti-oxidative; anti-inflammatory;
anti-hypertensive; regulation of lipid and
glucose metabolism; reduction of
nephrotoxicity
Free radical scavenging; inhibition of
pro-inflammatory mediator; iNOS/i-mtNOS;
optimisation of nNOS/c-mtNOS; reduction
of factor 1-α and NF-κB; downregulation of
Bcl-2 and activation of p53 and CD95;
increase in catalase activity and reduction
in thiobarbituric acid reactive substrates;
reduction in lipid peroxidation, creatinine,
uric acid and blood urea nitrogen levels
In vitro, animal studies, placebo-controlled
RCTs [80, 90, 92, 106, 109–114]
Gastrointestinal conditions Anti-oxidative; anti-inflammatory Free radical scavenging; inhibition of
pro-inflammatory cytokines, cell adhesion
molecules, NO production, COX-2
expression, NF-κ activation; regulation of
macrophage activity
Animal studies, RCTs [50, 79–81, 92, 114, 115]
Neonatology and paediatrics Anti-inflammatory; anti-oxidative; sedative Reduction of pro-inflammatory cytokines
(IL-6, IL-8 and TNF-α) and nitrite/nitrate
levels; inflammatory-derived activation of
phospholipase A2, lipoxygenase and
cyclooxygenases; increased glutathione
peroxidase activity; reduction of C-reactive
protein
Animal and human studies, RCTs,
open-label [116–119]
Neurodegenerative disorders Protection against neurodegeneration
caused by mitochondrial dysfunction and
oxidative/nitrosative stress; apoptosis;
prevention of vasoconstriction of cerebral
arteries
Activations of mitochondrial cell survival
pathways; regulation of apoptosis;
silencing of the Rip2/Caspase-1 pathway;
reduced mitochondrial inducible NO
synthase; increased activity of respiratory
complexes I, III and IV; increased activity
and expression of antioxidant enzymes;
high lipophilicity
Animal and human studies, SRs
[46, 49, 79, 81, 90, 94, 100, 106, 120–124]
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respectively. Table 4 summarises reviews with overlapping
conditions (Fig. 2). The key data from the included SRs or
NRs are summarised in Additional file 1: Table S1 and
Additional file 2: Table S2. Additional file 3: Table S3 gives
the methodological quality of the papers included.
Additional file 4: Table S4 lists all randomised controlled
trials (RCTs) covered in the subset of 31 SRs and indicates
the amount of overlap (Fig. 3). Additional file 5: Table S5
Table 1 Biological functions and processes that may be affected by MLT and suggested mechanisms of action in various models
(Continued)
Function or process Effects Suggested mechanisms Type of evidence (references)
Mental disorders Anti-inflammatory; anti-nociceptive;
anxiolytic; drug detoxification
Regulating cytokine production of
immunocompetent cells; reducing adhesion
molecules and pro-inflammatory cytokines
including IL-6, IL-8 and TNF; modifying serum
inflammatory parameters; neutralising free
radicals and non-radical oxygen-based
reactants
Animal and human studies
[34, 66, 123, 125–130]
Pain syndromes Anti-nociceptive, antiallodynic and
analgesic effects; synchronisation of
biological rhythms
Activation of melatoninergic MLT1/MLT2
receptors; release of opioid peptides
(β-endorphins); interaction with opioid,
γ-aminobutyric acid or N-methyl-daspartate
receptors; NO-arginine pathway; antioxidant
and anti-inflammatory effect; regulation of
endoplasmic reticulum and mitochondrial
activity
Animal and human studies
[33, 117, 131, 132]
Reproductive functions Antioxidant, anti-inflammatory,
anti-apoptotic, cytoprotective and
neuroprotective effects; reduced risk of
complications; increased homeostasis;
gonadotropin secretion; higher rate of
mature oocytes and quality embryos
Activation of melatoninergic MLT1/MLT2
receptors; inhibition of adenyl cyclase
activity; forskolin-induced cAMP formation
with subsequent reduction in activated
protein kinase; alteration of granulosa cell
steroidogenesis and folliculogenesis;
corpus luteum function; inhibition of
prostaglandins, oxytocin, cortisol
production and LDL peroxidation;
activation of prolactin secretion; free
hydroxyl radicals scavenging; prevention
against DNA damage; activation of
superoxide dismutase, glutathione
peroxidase, glutathione reductase and
glucose-6-phosphate dehydrogenase;
inhibition of NO synthase; deferred
apoptosis of villous cytotrophoblasts and
protection of syncytiotrophoblasts;
improved haemodynamics and nutrient
transfer at the placental-uterine interface
In vitro, animal and human studies
[62, 95, 115, 119, 133–139]
Sleep disorders Sleep enhancer; shifted circadian rhythms;
reduced duration of jet lag
Activation of alpha-2 noradrenergic
receptor agonist clonidine; lowered core
body temperature; opening of the sleep
gate and facilitation of re-entrainment to
suprachiasmatic nuclei; potentiation of
GABA on GABAA receptors; inactivation of
calmodulin
RCTs [26, 29, 39, 42, 64, 67, 70, 80, 81, 90,
92, 94, 103, 105–107, 124, 140–161]
Traumatic CNS injury Attenuation of neural damage;
neuroprotective effects; inhibition of
necrosis, apoptosis; immunomodulation;
protection of nuclear and mitochondrial
DNA; anti-oxidative effects
Free radical scavenging (including the
hydroxyl radical, hydrogen peroxide,
singlet oxygen, NO, peroxynitrite anion
and peroxynitrous acid); inhibition of
pro-inflammatory cytokines or quinone
reductase 2, calcium ion-mediated toxicity,
proxidative enzymes NO synthase,
lipoxygenase and phospholipase A2;
activation of the tumour necrosis factor
receptors; increased efficiency of oxidative
phosphorylation; reduction of NF-κB or TNF
expression; modulation of angiogenesis;
stimulation of superoxide dismutase,
glutathione peroxidase, glutathione
reductase, catalase and glutathione;
induction of γ-glutamylcysteine synthetase;
activation of glucose-6-phosphate
dehydrogenase
In vitro, animal and human studies
[27, 32, 46, 61, 94, 106, 162–168]
ATP adenosine triphosphate, cANP cyclic adenosine monophosphate, c-mtNOS constitutive mitochondrial nitric oxide synthase, CNS central nervous system,
COX-2 cyclooxygenase 2, GABA gamma-aminobutyric acid, iNOS inducible nitric oxide synthase, i-mtNOS inducible mitochondrial nitric oxide synthase, LDL low-density
lipoproteins, MLT melatonin, NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells, NK natural killer, nNOS neuronal nitric oxide synthase, NO nitric oxide,
mPTP mitochondrial permeability transition pore, RCT randomised controlled trial, SR systematic review, TNFα tumour necrosis factor α
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lists adverse effects (AEs) reported in SRs. Altogether, 31
reviews were synthesised quantitatively, whereas the
remaining 164 reviews were synthesised narratively.
Characteristics of studies included (N = 195)
The number of primary studies in each SR ranged from
0 to 68 (mean 6.5 ± 10.78). The total number of
participants was inestimable due to overlapping studies
(optional range 61 to 5812). In 117 of the reviews (60%),
either the number of primary studies or the number of
participants was not available. None of the included SRs
or MAs had access to individual participant data and all
relied on summary-level data from the published litera-
ture. Eighteen SRs relied on continuous data for their
respective MAs [standardised mean difference (SMD),
mean difference (MD) and weighted mean difference
(WMD)]; and 12 (6.1%) used dichotomous data for pool-
ing [odds ratio (OR) and risk ratio (RR)]; with only one
MA using both types of data and analyses (RR and MD)
[25]. Three MAs used effect sizes for presenting the
overall estimates [26–28].
Various conditions were evaluated, ranging from acute
coronary syndrome to various cancers, with insomnia/
sleep disorders being the most frequent (N = 50; 25.6%).
Of these, 26 focused on insomnia/primary sleep disor-
ders only, whereas the remaining 24 evaluated other
health conditions with underlying (secondary) sleep dis-
orders. Four reviews (2%) included healthy individuals;
and six (3%) evaluated a mixture of healthy and un-
healthy patients. Human studies varied from case studies
(N = 4), case series (N = 4), case control (N = 2), cohort
(N = 1), open-label (N = 13) and uncontrolled before–
after (N = 2) to RCTs of parallel and cross-over design
with or without the use of a placebo (N = 71).
Administration routes varied from oral and intra-
venous to sublingual; and MLT preparations included
patches, pills, capsules and solutions. In total, 99 reviews
(50.7%) included animal/in vivo studies and 55 reviews
(28.2%) also included in vitro studies, whereas 84 re-
views (43%) included humans only. Confounding factors
were not mentioned in 82 reviews (42%). In the
remaining 113 reviews, both exogenous and endogenous
MLT levels were influenced by a range of genetic,
epigenetic and environmental factors including age, gen-
der, menopausal status, parity, oestrogen levels, lifestyle
(alcohol use, body mass index, body posture, caffeine,
diet, supplements, drug use, night-shift work, artificial light
at night, physical activity, psychological stress and sleep
hygiene) and others, including individual chronotypes,
sessional variations and time, dose and route of MLT
administration. In medically compromised patients, e.g.
those with cancer, MLT was frequently used as an adjunct
to usual care or conventional treatment such as chemo-
therapy, radiotherapy, supportive care and palliative care.
The most commonly cited effects of MLT were its
anti-oxidative, anti-inflammatory and immunomodula-
tory properties (Table 1). In neoplastic diseases, the most
common mechanisms of action included free radical
scavenging (hydroxyl radical, hydrogen peroxide, hypo-
chlorous acid, singlet oxygen, the peroxynitrite anion
and peroxynitrous acid); stimulation of immune system;
improvement of oxidative phosphorylation and ATP
generation; co-activating protein kinase enzymes; reduc-
tion of cellular proliferation; inhibition of angiogenesis;
prostaglandin E2 or 17β-oestradiol; the uptake of linoleic
acid, DNA methyltransferase or telomerase.
Evaluation of the evidence
Four MAs [25, 29–31] had large levels of heterogeneity
(I2 ≥ 50% and ≤ 75%) and six SRs [32–37] had very large
levels of heterogeneity (I2 > 75%). The median number of
studies per MA was 5 (IQR = 4.75) with a median of 557
Table 4 Reviews with overlapping conditions
Subjects/condition/health outcome/indication Number of systematic
reviews (N)
Ageing 5
Cancer 43
Cardiovascular 9
Delirium 2
Epilepsy 2
Excretory/renal functions 2
Gastrointestinal function/conditions 7
Healthy adults 6
Infections (various) 6
Inflammatory conditions 10
Menopause (symptoms) 2
Musculoskeletal system 3
Neonates, infants and children
(various conditions)
9
Nervous system (central and peripheral)
conditions/injuries
18
Neurodegenerative disorders/dementias 10
Obesity/metabolic diseases 10
Other (miscellaneous) 6
Oral cavity diseases 3
Pain syndromes 5
Pregnancy/reproductive functions/infertility 11
Pre-operative, peri-operative or post-operative
care (anxiety, prevention of agitation)
4
Protection against radiation/metal toxicity 4
Psychiatric/psychological conditions 22
Sleep outcomes/insomnia 37
Various clinical conditions 10
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participants (IQR = 1561). In each of the 13 MAs, more
than 1000 cases were analysed. For sleep latency, pre-
operative anxiety, prevention of agitation or risk of
breast cancer, ten (32%) of 31 MAs reported effects that
were significant at P values less than 0.05 under the
random-effects model, and seven (23%) were significant
at P values less than 0.001 under the random-effects
model [31, 33, 38–41]. For eight MAs (25.8%), we were
unable to calculate 95% PIs. The remaining 23 MAs had a
95% PI that included the null value, meaning that,
although on average MLT improves various health out-
comes, this might depend on dose, duration, intensity,
age, gender or underlying co-morbidities. Evidence for
small-study effects was noted in three MAs (9.6%). These
MAs pertained to the incidence of delirium [35], spinal
cord injury [32] or post-operative pain [33] (Table 2).
Only one review [39] for the association of MLT and
sleep quality met our predefined convincing association
criterion. It highlighted that ramelteon can improve
sleep quality in insomnia (SMD = -0.08, 95% CI = -0.13
to -0.03). If we reduced the minimum number of partici-
pants in an MA to ≥500, then one more review [31]
would satisfy the inclusion criterion. It highlighted that
melatonin therapy can improve the partial and complete
Fig. 2 Health conditions with more than ten systematic reviews
Fig. 3 Distribution of citations of different RCTs in the subset of 31 SRs and MAs included. MA meta-analysis, RCT randomised controlled trial, SR
systematic review
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remission of solid tumour cancers (RR = 1.95, 95% CI =
1.49 to 2.54).
Quality of SRs
The quality of the reviews as measured with the Oxman
checklist was typically low (range = -9 to 9; mean = -4.5,
SD = 6.7) (Additional file 3: Table S3). Of the reviews in-
cluded, 153 (153/195; 78.4%) did not use appropriate
methods for combining studies and hence were scored
as -1.
Quality (and number) of primary studies
Altogether 154 reviews (78.9%) did not evaluate the
methodological quality of the primary studies (no
validity assessments). In 41 reviews (21.1%) that did
undertake this, the methodological quality of the pri-
mary data ranged from poor (N = 5) to high (N = 13),
with moderate being most commonly reported (N = 18),
as assessed by the Cochrane Risk of Bias Tool or the
Jadad Scale. The median number of primary studies
included was N = 9 (when possible to estimate).
Melatonin receptor agonists
Melatonin receptor agonists, such as Circadin® (prolonged-
release MLT), ramelteon, agomelatine or tasimelteon, bind
to and activate the MLT receptors 1 and 2 [42]. These ana-
logues of MLT are believed to have the same mechanisms
of action as MLT and are typically used for the treatment
of sleep disorders and depression [43]. Two reviews of
Circadin (prolonged-release MLT), four of ramelteon, two
of agomelatine and one of tasimelteon were included. The
duration, intensity and frequency varied across the reviews,
with 8 mg being most commonly used in ramelteon
studies, 2 mg for Circadin; 25–50 mg for agomelatine and
1–50 mg for tasimelteon.
Endogenous vs. exogenous MLT
In total, 31 reviews (15.8%) evaluated both exogenous
and endogenous MLT. However, it was often difficult to
ascertain the number of studies looking at exogenous
MLT vs. endogenous MLT only. The exogenous vs. en-
dogenous MLT doses are also incomparable, as the
routes of administration and types of studies differed
considerably (optional range 0.003 mg to 3 g).
Discussion
This umbrella review aimed to summarise and critically
evaluate the evidence from SRs and NRs of the effects of
MLT on health and to identify the biological mechanisms
of action involved. In total, 195 reviews were included (96%
of the reviews were published after 2000). Of the reviews,
99 included evidence from in vitro or animal experiments,
which highlights the still experimental phase of some MLT
research and the translational potential for human trials.
There was a considerable clinical and methodological
heterogeneity in terms of populations evaluated (from neo-
nates to elderly), doses, excipients, quality or purity of MLT
preparations, comparators, outcome measures, study
designs, lengths of follow-ups, settings, etc. Despite that,
the present review does lend support to the notion that en-
dogenous and exogenous MLT is associated with improved
health outcomes. However, caution is advised for the use or
supplementation of MLT in some autoimmune conditions,
such as rheumatoid arthritis, asthma or organ transplant-
ation as MLT has been reported to stimulate the function
of the immune system via the production of interleukins
(IL-1, IL-2, IL-6 and IL-12), interferon γ (IFN-γ), Th cells,
cytotoxic T cells, and B- and T-cell precursors [44].
Overall, though it seems that the connection between
MLT and health is well founded, there is less evidence
connecting MLT with specific diseases in a systematic
way. The physiological role of MLT, as uncovered by
various experimental studies, does, quite robustly, point
to a direct relation between MLT and critical elements
of health. However, the connection with specific condi-
tions needs to be researched comprehensively. Thus, we
suggest the need for high-quality primary data and we
underline the importance of targeted studies on specific
conditions, such Alzheimer’s or cardiovascular diseases.
Mechanisms of action
Some of the effects of MLT are via anti-oxidative (e.g.
[45–49]), anti-inflammatory (e.g. [50–52]), anti-apoptotic
(e.g. [53, 54]), anti-nociceptive (e.g. [33, 55]), anti-
hypertensive (e.g. [56–58]), cytoprotective, neuroprotec-
tive, cardioprotective or nephroprotective effects (e.g.
[59–64]), and by enhancing mitochondrial function and
protecting nuclear and mitochondrial DNA or regulating
homeostasis (e.g. [53, 65]; Table 1). Even though some of
the mechanisms of action are well established, the relative
absence of the exact role of confounding factors such as
diet, exercise, sleep and genetics on the role of MLT to
health limits the generalisability of the results. We here
identify three important factors that can be taken into
account by future researchers. Firstly, the climatic
conditions – and especially latitude – could bias the
physiological response. Secondly, the urban environment
of cities and the presence of LED light could disrupt circa-
dian rhythms and suppress the production of MLT.
Finally, the overall cultural background could also have a
significant impact, as this affects nutrition and clothing.
Safety
AEs of exogenous MLT and MLT analogues were re-
ported in 11 (5.6%) of the included reviews. Two reviews
pooled the safety data [40, 66]. In Liu and Wang [40],
there were more subjective reports of at least one AE
after treatment with ramelteon compared to placebo
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(RR = 1.11, 1.03 to 1.20, P < 0.01; seven studies). In
Huang et al. [66], however, agomelatine revealed a lower
rate of discontinuation due to AEs compared with selective
serotonin reuptake inhibitors or serotonin–norepinephrine
reuptake inhibitors (RR = 0.38, 95% CI = 0.25 to 0.57). AEs
were typically mild and included worsening of symptoms
(seizures, asthma or headaches), transient headaches and
dizziness, abdominal pain, pharyngitis, back pain and as-
thenia, somnolence, fatigue, nasopharyngitis, upper re-
spiratory infection, nausea, dizziness, diarrhoea, dyspepsia,
dysmenorrhoea, diarrhoea, dry mouth, increased alanine
aminotransferase, nightmares, morning drowsiness, enur-
esis, rash and hypothermia (Additional file 5: Table S5).
Given the overwhelming benefits of MLT treatment and
the existence of very few and mild AEs (also for long-term
use), the risk–benefit ratio favours MLT.
Cost-effectiveness
Only two reviews undertook any health economic ana-
lysis of MLT. One review stated that the cost of a 30-
tablet pack of 2 mg of Circadin was £15.39 [67], whereas
Liira et al. [38] ‘did not find evidence on the cost-
effectiveness of the drugs in the included trials’. More
cost-effectiveness or cost-benefit analyses would be re-
quired to confirm the economic benefits of MLT and to
inform various stakeholders and policymakers.
Quality (and quantity) of primary data
In 154 (78.9%) of the reviews, the quality of the primary
data was not evaluated. In the 41 reviews (21%) that did
evaluate it, the quality of the primary data ranged from
poor to high (average =moderate), as judged by the au-
thors of the included reviews, primarily using the
Cochrane Risk of Bias Tool. The relatively low number of
primary studies (median 9) included in the SRs or NRs
might be of potential concern, and signals the need for
more research into a wide range of conditions and clinical
areas including oncology, emergency medicine, neurology,
metabolic diseases, cardiovascular medicine, gynaecology,
paediatrics, psychiatry, mental health, gastrointestinal dis-
eases and pain management.
Review quality
The methodological quality of the included SRs was fre-
quently poor (Additional file 3: Table S3). Most of the
articles that scored poorly on the Oxman checklist
(quality rating scale) were NRs, which are often of
poorer quality compared to SRs. As these articles do
contribute relevant information, we decided to include
them in our study. Of the reviews, however, 36 (18.4%)
scored 6–9 on the Oxman checklist, meaning they had
minimal or no flaws.
Strengths and weaknesses
This umbrella review has important strengths, such as
the inclusion and critical appraisal of 195 review articles,
identification of gaps and uncertainties in the evidence
base, and categorisation of significant health-related ef-
fects and associated mechanisms of action. However, this
umbrella review of both SRs and NRs has several limita-
tions that ought to be kept in mind when interpreting
its results. First and foremost, even though comprehen-
sive searches were employed, there is no guarantee that
all relevant SRs of MLT were included. The searches
were restricted to the past 21 years, thereby omitting
some potentially older and potentially important re-
views, as well as reviews published in languages other
than English.
Secondly, one of the limitations of our overview is that
many SRs often analysed the same primary studies. This
overlap between SRs is important when interpreting re-
sults of this overview (Additional file 4: Table S4, Fig. 2).
For instance, due to the double counting of the patient
data resulting from the overlapping studies, the total
number of patients included in our analyses is inestim-
able. Also, in the subset of 31 MAs, 238 RCTs were in-
cluded. These RCTs were frequently used in more than
one MA (range = 1–4, mean = 1.4, SD = 0.66), meaning
that there were overlapping studies and double counting
of the data (Fig. 2). To further illustrate this, three [31,
37, 68] of five MAs [31, 37, 68–70] evaluating MLT for
cancers relied on the same data from the same four pri-
mary trials (Lissoni 1996, 1997, 1999, 2003). However,
the amount of overlap was calculated (corrected covered
area) and found to be 1.2%, which is 'slight' according to
Pieper's formula.
Thirdly, although, four SRs were methodologically
sound (Oxman checklist score ≥ 6), they were based on
poor-quality primary data, which (logically) might seem
contradictory.
Fourthly, we did not evaluate whether there was evi-
dence for small-study effects using funnel plot asym-
metry [23] (publication bias) because of insufficient data.
Fifthly, reviewing SRs might abandon the nuances that
may be embedded in the original data, such as conflicts of
interest, sources of funding, validity, generalisability etc.
Sixthly, various animal, human and in vitro models;
different modes of administration; and exogenous and
endogenous MLT were frequently analysed together,
thereby giving limited understanding of how the results
vary depending on the health outcomes evaluated.
Lastly, there is no commonly accepted cut-off point
differentiating NRs vs. SRs using the Oxman scoring sys-
tem. For example, a review that arbitrarily scored 2–3
on the scale (indicating the presence of major flaws)
may be arbitrarily assigned as an NR as well as an SR
(the definition being arbitrary too). In another example,
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reviews that could be arbitrarily judged as narrative with
extensive flaws (a score of 1 or below), e.g. De Jonghe et
al. [71], may include information about the number of
primary studies and total sample size, i.e. 9/330. On the
other hand, reviews that had no flaws (a score of 6–9)
may not have that information, e.g. Liira et al. [38].
Taken together, these limitations reduce the conclusive-
ness of our findings, making them prone to criticism.
Conclusions
Despite the abundance of evidence, more systematic
research is needed to understand and establish the
connection between MLT and specific aspects of health,
potentially as a function of important lifestyle choices.
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Appendix
The search strategy for MEDLINE (via Ovid)
1. Melatonin.mp.
2. exp Melatonin/
3. urinary 6-sulfatoxymelatonin.mp.
4. 1-3/or
5. Health.mp.
6. exp Health/
7. 5-6/or
8. Review.ti,ab.
9. 4 AND 7 AND 8
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